AbbVie (ABBV) SVP David Ryan Purdue reports 2,108-share tax withholding

Rhea-AI Filing Summary

AbbVie Inc. senior vice president and controller David Ryan Purdue reported a routine tax-related share disposition. On February 27, 2026, 2,108 shares of AbbVie common stock were withheld at $232.08 per share to cover tax obligations, a non-market transaction coded as a tax-withholding disposition.

After this event, Purdue directly held 8,468 shares of AbbVie common stock. He also had an additional 543 shares held indirectly through a profit sharing trust tied to an AbbVie savings program, with that balance stated as of February 20, 2026 and including shares from dividend reinvestment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Purdue David Ryan

(Last) (First) (Middle)

1 NORTH WAUKEGAN ROAD

(Street)

NORTH CHICAGO IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Controller

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
03/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.01 par value	02/27/2026		F		2,108	D	$232.08	8,468	D
Common Stock, $0.01 par value								543(1)	I	Profit sharing trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Balance in AbbVie Savings program as of February 20, 2026. Balance includes shares acquired pursuant to a dividend reinvestment feature.

Remarks:

Amended to correct the number of shares withheld for taxes at vesting as reported on the original Form 4 filed March 3, 2026. The original filing reflected an incorrect withholding rate. All other information remains unchanged.

	/s/ T.O. Odutayo, Attorney-in-Fact for David R. Purdue	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did AbbVie (ABBV) SVP David Ryan Purdue report?

AbbVie SVP and controller David Ryan Purdue reported a tax-withholding disposition of 2,108 shares of common stock. The shares were withheld on February 27, 2026 at $232.08 per share to satisfy tax obligations, not as an open-market sale.

Was the AbbVie (ABBV) insider transaction a market sale of shares?

No, the AbbVie insider event was a tax-withholding disposition, not an open-market sale. Shares were delivered to cover tax liabilities related to equity compensation, meaning the transaction does not reflect an active decision to sell shares in the open market.

How many AbbVie (ABBV) shares does David Ryan Purdue hold after the filing?

Following the tax-withholding transaction, David Ryan Purdue directly held 8,468 AbbVie shares. In addition, he had 543 shares held indirectly through a profit sharing trust associated with an AbbVie savings program, as disclosed in the footnote to the filing.

What does the profit sharing trust holding mean for AbbVie (ABBV) SVP Purdue?

The filing states that 543 AbbVie shares are held indirectly for David Ryan Purdue through a profit sharing trust. A footnote explains this represents his AbbVie savings program balance as of February 20, 2026, including shares acquired through a dividend reinvestment feature.

How is the AbbVie (ABBV) tax-withholding transaction coded in the Form 4/A?

The transaction is coded “F”, which indicates payment of tax liability by delivering securities. The filing describes this as a tax-withholding disposition of 2,108 AbbVie common shares, rather than a discretionary purchase or sale on the open market.

Does the AbbVie (ABBV) insider filing show any option exercises or derivative activity?

No option exercises or other derivative transactions are listed in this Form 4/A. The transaction summary shows no derivative exercises and highlights only one tax-withholding disposition and one holding entry, with the derivative position table remaining empty.